Insulet Corp (PODD) 34.36 $PODD
Insulet Corporation to Present at the Canaccord Genuity 34th Annual Growth Conference
Marketwire - Fri Aug 01, 3:15PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced the Company will participate in the Canaccord Genuity 34th Annual Growth Conference at the InterContinental Boston. Management is scheduled to present an overview of the Company on Thursday, August 14, 2014 at 1:00 p.m. ET.
Insulet Corporation to Report Second Quarter 2014 Financial Results on August 7, 2014
Marketwire - Tue Jul 29, 3:15PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, announced plans to release its financial results for the second quarter of 2014 on August 7, 2014 after the close of the financial markets.
Insulet Corporation (NASDAQ: PODD) to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Tue Jul 29, 9:00AM CDT
What:
GliaCure Appoints New Member to Board of Directors
PR Newswire - Thu Jul 24, 11:48AM CDT
GliaCure, Inc., a company focused on developing novel, non-neuronal therapies for a range of neurological and neuropsychiatric disorders, announced today that it has appointed Joseph S. Zakrzewski to the Company's Board of Directors.
Technical Snapshot on Health Care Equipment Stocks -- Research on Hologic, CareFusion, Insulet, and Becton Dickinson
PR Newswire - Fri Jun 27, 6:20AM CDT
On Thursday, June 26, 2014, the NASDAQ Composite ended at 4,379.05, down 0.02%, the Dow Jones Industrial Average finished the session at 16,846.13, down 0.13% and the S&P 500 closed at 1,957.22, down 0.12%. During the trading session, six out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 708.54, up 0.06%, and the index has gained 5.43% in the previous three months. Investor-Edge has initiated coverage on the following equities: Hologic Inc. (NASDAQ: HOLX), CareFusion Corp. (NYSE: CFN), Insulet Corp. (NASDAQ: PODD) and Becton Dickinson and Co. (NYSE: BDX). Free technical research on HOLX, CFN, PODD and BDX can be downloaded upon signing up at:
Global Insulin Delivery Devices Market 2014-2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers
M2 - Tue Jun 24, 3:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6qt2hc/insulin_delivery) has announced the addition of the "Insulin Delivery Devices Market to 2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers" report to their offering. 'Insulin Delivery Devices Market to 2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers' looks at the market, competitive landscape, and trends for the four insulin delivery devices market segments: insulin pens, insulin pumps, insulin syringes and traditional insulin pump accessories. It provides comprehensive information on the key trends affecting these segments, and key analytical content on the market dynamics. The report also reviews the competitive landscape, analyzes each segment's pipeline products and gives details of important M&A deals. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Key geographies: the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia and Brazil. - Information on market size for the four insulin delivery devices market segments: insulin pens, insulin pumps, insulin syringes and traditional insulin pump accessories. - Annualized market revenue data forecast to 2019 and company share data for 2012. - Qualitative analysis of key trends in the insulin delivery devices market. - Information on the competitive landscape and the leading technologies of key players: Novo Nordisk A/S, Medtronic, Inc., Sanofi, Eli Lilly and Company, Becton, Dickinson and Company, Animas Corporation, Insulet Corporation, F. Hoffmann-La Roche Ltd., Abbott Laboratories. - Information on reimbursement trends and market access for key countries. Reasons to buy - Develop business strategies by understanding the trends and developments driving the global insulin delivery devices market. - Design and enhance your product development, marketing, and sales strategies. - Exploit M&A opportunities by identifying the market players with the most innovative pipelines. - Develop market-entry and market-expansion strategies. - Identify the key players best positioned to take advantage of the emerging market opportunities. - Exploit in-licensing and out-licensing opportunities by identifying the products most likely to ensure a robust return. - Identify, understand and capitalize on the next big thing in the insulin delivery devices market landscape. - Make more informed business decisions from insightful and in-depth analysis of the global insulin delivery devices market and the factors shaping it. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Diabetes - Disease Overview 4 Diabetes - Epidemiology 5 Global Insulin Delivery Devices Market: Device Overview 6 Global Insulin Delivery Devices Market: Market Characterization 7 Global Insulin Delivery Devices Market: Segment Analysis and Forecasts 8 Global Insulin Delivery Devices Market: Country Analysis and Forecasts 9 Global Insulin Delivery Devices Market: Reimbursement System 10 Global Insulin Delivery Devices Market: Competitive Landscape 11 Global Insulin Delivery Devices Market: Product Pipeline Analysis 12 Global Insulin Delivery Devices Market: Consolidation Landscape 13 Appendix Companies Mentioned - Abbott Laboratories - Animas - Antares Pharma - Asante Solutions - Becton, Dickinson and Company - Bioject Medical Technologies - Eli Lilly - F. Hoffmann-La Roche - Injex - Equidyne Systems - Insulet - Medtronic - Novo Nordisk (Subsidiary of Novo A/S) - Owen Mumford - Sanofi - Shanghai Fosun Pharmaceutical - Tandem Diabetes Care - Tonghua Dongbao Pharmaceutical - Ypsomed For more information visit http://www.researchandmarkets.com/research/6q...n_delivery
DexCom Collaborates with Insulet Corporation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 2:30PM CDT
The decision to integrate Insulet's (PODD) OmniPod System data into DexCom's (DXCM) mobile App platform is a part of DexCom's (DXCM) open architecture approach to diabetes-related data.
Insider Trading Alert - PODD, UVV And PG Traded By Insiders
at The Street - Mon Jun 16, 9:15AM CDT
Stocks with insider trader activity include PODD, UVV and PG
DexCom's Forthcoming Mobile App Platform to Integrate Data from Insulet's OmniPod System
Business Wire - Fri Jun 13, 3:01PM CDT
Insulet Corporation (NASDAQ: PODD) and DexCom, Inc. (NASDAQ: DXCM) announced today their intention to enable DexCom's mobile App platform, which is currently under development, to integrate data from Insulet's OmniPod System. This will be the first version of a mobile App that is capable of incorporating glucose and other diabetes-related data from patients' devices and displaying the integrated data via a smartphone App. This event also marks the start of DexCom's open architecture approach to diabetes-related data which will include an "approved by DexCom" indication to validate the authenticity of devices and Apps integrating DexCom CGM data.
Insider Trading Alert - PODD, NRG And IT Traded By Insiders
at The Street - Wed Jun 11, 10:31AM CDT
Stocks with insider trader activity include PODD, NRG and IT
Public Offerings, Product Launches, and Upcoming Conferences - Analyst Notes on Insulet, CR Bard, Covidien, Thoratec and Hill-Rom
PR Newswire - Mon Jun 09, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Insulet Corporation (NASDAQ: PODD), CR Bard Inc. (NYSE: BCR), Covidien plc (NYSE: COV), Thoratec Corp. (NASDAQ: THOR) and Hill-Rom Holdings, Inc. (NYSE: HRC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3473-100free.
NDA Resubmission, Clinical Data and Findings, and Conference Participations - Analyst Notes on InterMune, ResMed, Seattle Genetics, Insulet and Charles River
PR Newswire - Thu Jun 05, 5:30AM CDT
Today, Analysts Review released its analysts' notes regarding InterMune Inc. (NASDAQ: ITMN), ResMed Inc. (NYSE: RMD), Seattle Genetics Inc. (NASDAQ: SGEN), Insulet Corporation (NASDAQ: PODD) and Charles River Laboratories International, Inc. (NYSE: CRL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3390-100free.
Insulet Announces Pricing of Convertible Senior Notes
Marketwire - Thu Jun 05, 2:06AM CDT
Insulet Corporation (NASDAQ: PODD) today announced the pricing of a public offering of $175 million principal amount of convertible senior notes due 2019 (the "notes"
. The notes will bear interest at an annual rate of 2.00% and will mature on June 15, 2019, unless earlier converted, purchased or redeemed. Insulet also granted the underwriter an option to purchase up to an additional $26.25 million principal amount of notes to cover over-allotments, if any.
Insulet Announces Public Offering of Convertible Senior Notes
Marketwire - Thu Jun 05, 1:55AM CDT
Insulet Corporation (NASDAQ: PODD) today announced its intention to offer, subject to market and other conditions, $175 million principal amount of convertible senior notes due 2019 (the "notes" pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC" today. Insulet also intends to grant the underwriter an option to purchase up to an additional $26.25 million principal amount of notes to cover over-allotments, if any.
Insulet Corporation to Present at Upcoming Investor Conferences
Marketwire - Thu May 29, 3:16PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced the Company will participate in the following upcoming investor conferences:
Technical Coverage on Health Care Sector Equities -- Research on Becton, Dickinson and Co., Insulet, Antares Pharma, and Haemonetics
PR Newswire - Tue May 27, 6:00AM CDT
On Friday, May 23, 2014, the NASDAQ Composite ended at 4,185.81, up 0.76%, the Dow Jones Industrial Average finished the day 0.38% higher at 16,606.27, and the S&P 500 closed at 1,900.53, up 0.42%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 681.33, up 0.08%, and the index has advanced 2.63% in the previous one month. Investor-Edge has initiated coverage on the following equities: Becton, Dickinson and Company (NYSE: BDX), Insulet Corporation (NASDAQ: PODD), Antares Pharma Inc. (NASDAQ: ATRS) and Haemonetics Corp. (NYSE: HAE). Free technical research on BDX, PODD, ATRS and HAE can be downloaded upon signing up at:
Downtrend Call Working As Insulet Stock Falls 26.7% (PODD)
Comtex SmarTrend(R) - Fri May 23, 9:54AM CDT
SmarTrend identified a Downtrend for Insulet (NASDAQ
ODD) on March 31st, 2014 at $46.97. In approximately 2 months, Insulet has returned 26.68% as of today's recent price of $34.44.
Shares of PODD Up 33.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Mar 26, 4:43PM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ ODD) on November 29th, 2013 at $36.86. In approximately 4 months, Insulet has returned 33.32% as of today's recent price of $49.14.
Sean Busby Becomes First Person With Type 1 Diabetes to Successfully Backcountry Snowboard All Seven Continents
Marketwire - Thu Mar 20, 9:36AM CDT
Riding On Insulin, a nonprofit organization that empowers, activates and connects the global diabetes community through shared experience and action sports, and Insulet (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, are proud to announce that professional snowboarder Sean Busby has become the first person with type 1 diabetes (T1D) to successfully backcountry snowboard on each of the seven continents. Sean, an OmniPod ambassador and the founder of Riding On Insulin, began his seven-continent mission in 2008, just four years after he was diagnosed with type 1 diabetes while training for the 2010 Olympics. From Antarctica in 2008 to Africa in 2014, Sean explored remote corners of the globe while proving that T1D can't stop people from reaching the highest peaks in life.
Insulet Corporation to Present at the Canaccord Genuity 34th Annual Growth Conference
Marketwire - Fri Aug 01, 3:15PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced the Company will participate in the Canaccord Genuity 34th Annual Growth Conference at the InterContinental Boston. Management is scheduled to present an overview of the Company on Thursday, August 14, 2014 at 1:00 p.m. ET.
Insulet Corporation to Report Second Quarter 2014 Financial Results on August 7, 2014
Marketwire - Tue Jul 29, 3:15PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, announced plans to release its financial results for the second quarter of 2014 on August 7, 2014 after the close of the financial markets.
Insulet Corporation (NASDAQ: PODD) to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Tue Jul 29, 9:00AM CDT
What:
GliaCure Appoints New Member to Board of Directors
PR Newswire - Thu Jul 24, 11:48AM CDT
GliaCure, Inc., a company focused on developing novel, non-neuronal therapies for a range of neurological and neuropsychiatric disorders, announced today that it has appointed Joseph S. Zakrzewski to the Company's Board of Directors.
Technical Snapshot on Health Care Equipment Stocks -- Research on Hologic, CareFusion, Insulet, and Becton Dickinson
PR Newswire - Fri Jun 27, 6:20AM CDT
On Thursday, June 26, 2014, the NASDAQ Composite ended at 4,379.05, down 0.02%, the Dow Jones Industrial Average finished the session at 16,846.13, down 0.13% and the S&P 500 closed at 1,957.22, down 0.12%. During the trading session, six out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 708.54, up 0.06%, and the index has gained 5.43% in the previous three months. Investor-Edge has initiated coverage on the following equities: Hologic Inc. (NASDAQ: HOLX), CareFusion Corp. (NYSE: CFN), Insulet Corp. (NASDAQ: PODD) and Becton Dickinson and Co. (NYSE: BDX). Free technical research on HOLX, CFN, PODD and BDX can be downloaded upon signing up at:
Global Insulin Delivery Devices Market 2014-2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers
M2 - Tue Jun 24, 3:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6qt2hc/insulin_delivery) has announced the addition of the "Insulin Delivery Devices Market to 2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers" report to their offering. 'Insulin Delivery Devices Market to 2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers' looks at the market, competitive landscape, and trends for the four insulin delivery devices market segments: insulin pens, insulin pumps, insulin syringes and traditional insulin pump accessories. It provides comprehensive information on the key trends affecting these segments, and key analytical content on the market dynamics. The report also reviews the competitive landscape, analyzes each segment's pipeline products and gives details of important M&A deals. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Key geographies: the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia and Brazil. - Information on market size for the four insulin delivery devices market segments: insulin pens, insulin pumps, insulin syringes and traditional insulin pump accessories. - Annualized market revenue data forecast to 2019 and company share data for 2012. - Qualitative analysis of key trends in the insulin delivery devices market. - Information on the competitive landscape and the leading technologies of key players: Novo Nordisk A/S, Medtronic, Inc., Sanofi, Eli Lilly and Company, Becton, Dickinson and Company, Animas Corporation, Insulet Corporation, F. Hoffmann-La Roche Ltd., Abbott Laboratories. - Information on reimbursement trends and market access for key countries. Reasons to buy - Develop business strategies by understanding the trends and developments driving the global insulin delivery devices market. - Design and enhance your product development, marketing, and sales strategies. - Exploit M&A opportunities by identifying the market players with the most innovative pipelines. - Develop market-entry and market-expansion strategies. - Identify the key players best positioned to take advantage of the emerging market opportunities. - Exploit in-licensing and out-licensing opportunities by identifying the products most likely to ensure a robust return. - Identify, understand and capitalize on the next big thing in the insulin delivery devices market landscape. - Make more informed business decisions from insightful and in-depth analysis of the global insulin delivery devices market and the factors shaping it. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Diabetes - Disease Overview 4 Diabetes - Epidemiology 5 Global Insulin Delivery Devices Market: Device Overview 6 Global Insulin Delivery Devices Market: Market Characterization 7 Global Insulin Delivery Devices Market: Segment Analysis and Forecasts 8 Global Insulin Delivery Devices Market: Country Analysis and Forecasts 9 Global Insulin Delivery Devices Market: Reimbursement System 10 Global Insulin Delivery Devices Market: Competitive Landscape 11 Global Insulin Delivery Devices Market: Product Pipeline Analysis 12 Global Insulin Delivery Devices Market: Consolidation Landscape 13 Appendix Companies Mentioned - Abbott Laboratories - Animas - Antares Pharma - Asante Solutions - Becton, Dickinson and Company - Bioject Medical Technologies - Eli Lilly - F. Hoffmann-La Roche - Injex - Equidyne Systems - Insulet - Medtronic - Novo Nordisk (Subsidiary of Novo A/S) - Owen Mumford - Sanofi - Shanghai Fosun Pharmaceutical - Tandem Diabetes Care - Tonghua Dongbao Pharmaceutical - Ypsomed For more information visit http://www.researchandmarkets.com/research/6q...n_delivery
DexCom Collaborates with Insulet Corporation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 2:30PM CDT
The decision to integrate Insulet's (PODD) OmniPod System data into DexCom's (DXCM) mobile App platform is a part of DexCom's (DXCM) open architecture approach to diabetes-related data.
Insider Trading Alert - PODD, UVV And PG Traded By Insiders
at The Street - Mon Jun 16, 9:15AM CDT
Stocks with insider trader activity include PODD, UVV and PG
DexCom's Forthcoming Mobile App Platform to Integrate Data from Insulet's OmniPod System
Business Wire - Fri Jun 13, 3:01PM CDT
Insulet Corporation (NASDAQ: PODD) and DexCom, Inc. (NASDAQ: DXCM) announced today their intention to enable DexCom's mobile App platform, which is currently under development, to integrate data from Insulet's OmniPod System. This will be the first version of a mobile App that is capable of incorporating glucose and other diabetes-related data from patients' devices and displaying the integrated data via a smartphone App. This event also marks the start of DexCom's open architecture approach to diabetes-related data which will include an "approved by DexCom" indication to validate the authenticity of devices and Apps integrating DexCom CGM data.
Insider Trading Alert - PODD, NRG And IT Traded By Insiders
at The Street - Wed Jun 11, 10:31AM CDT
Stocks with insider trader activity include PODD, NRG and IT
Public Offerings, Product Launches, and Upcoming Conferences - Analyst Notes on Insulet, CR Bard, Covidien, Thoratec and Hill-Rom
PR Newswire - Mon Jun 09, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Insulet Corporation (NASDAQ: PODD), CR Bard Inc. (NYSE: BCR), Covidien plc (NYSE: COV), Thoratec Corp. (NASDAQ: THOR) and Hill-Rom Holdings, Inc. (NYSE: HRC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3473-100free.
NDA Resubmission, Clinical Data and Findings, and Conference Participations - Analyst Notes on InterMune, ResMed, Seattle Genetics, Insulet and Charles River
PR Newswire - Thu Jun 05, 5:30AM CDT
Today, Analysts Review released its analysts' notes regarding InterMune Inc. (NASDAQ: ITMN), ResMed Inc. (NYSE: RMD), Seattle Genetics Inc. (NASDAQ: SGEN), Insulet Corporation (NASDAQ: PODD) and Charles River Laboratories International, Inc. (NYSE: CRL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3390-100free.
Insulet Announces Pricing of Convertible Senior Notes
Marketwire - Thu Jun 05, 2:06AM CDT
Insulet Corporation (NASDAQ: PODD) today announced the pricing of a public offering of $175 million principal amount of convertible senior notes due 2019 (the "notes"
. The notes will bear interest at an annual rate of 2.00% and will mature on June 15, 2019, unless earlier converted, purchased or redeemed. Insulet also granted the underwriter an option to purchase up to an additional $26.25 million principal amount of notes to cover over-allotments, if any. Insulet Announces Public Offering of Convertible Senior Notes
Marketwire - Thu Jun 05, 1:55AM CDT
Insulet Corporation (NASDAQ: PODD) today announced its intention to offer, subject to market and other conditions, $175 million principal amount of convertible senior notes due 2019 (the "notes"
pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC" today. Insulet also intends to grant the underwriter an option to purchase up to an additional $26.25 million principal amount of notes to cover over-allotments, if any. Insulet Corporation to Present at Upcoming Investor Conferences
Marketwire - Thu May 29, 3:16PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced the Company will participate in the following upcoming investor conferences:
Technical Coverage on Health Care Sector Equities -- Research on Becton, Dickinson and Co., Insulet, Antares Pharma, and Haemonetics
PR Newswire - Tue May 27, 6:00AM CDT
On Friday, May 23, 2014, the NASDAQ Composite ended at 4,185.81, up 0.76%, the Dow Jones Industrial Average finished the day 0.38% higher at 16,606.27, and the S&P 500 closed at 1,900.53, up 0.42%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 681.33, up 0.08%, and the index has advanced 2.63% in the previous one month. Investor-Edge has initiated coverage on the following equities: Becton, Dickinson and Company (NYSE: BDX), Insulet Corporation (NASDAQ: PODD), Antares Pharma Inc. (NASDAQ: ATRS) and Haemonetics Corp. (NYSE: HAE). Free technical research on BDX, PODD, ATRS and HAE can be downloaded upon signing up at:
Downtrend Call Working As Insulet Stock Falls 26.7% (PODD)
Comtex SmarTrend(R) - Fri May 23, 9:54AM CDT
SmarTrend identified a Downtrend for Insulet (NASDAQ
ODD) on March 31st, 2014 at $46.97. In approximately 2 months, Insulet has returned 26.68% as of today's recent price of $34.44. Shares of PODD Up 33.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Mar 26, 4:43PM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on November 29th, 2013 at $36.86. In approximately 4 months, Insulet has returned 33.32% as of today's recent price of $49.14. Sean Busby Becomes First Person With Type 1 Diabetes to Successfully Backcountry Snowboard All Seven Continents
Marketwire - Thu Mar 20, 9:36AM CDT
Riding On Insulin, a nonprofit organization that empowers, activates and connects the global diabetes community through shared experience and action sports, and Insulet (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, are proud to announce that professional snowboarder Sean Busby has become the first person with type 1 diabetes (T1D) to successfully backcountry snowboard on each of the seven continents. Sean, an OmniPod ambassador and the founder of Riding On Insulin, began his seven-continent mission in 2008, just four years after he was diagnosed with type 1 diabetes while training for the 2010 Olympics. From Antarctica in 2008 to Africa in 2014, Sean explored remote corners of the globe while proving that T1D can't stop people from reaching the highest peaks in life.
